TGFB1 and Myocardial fibrosis: In a diabetic model, selective CB1 antagonists rimonabant (or SR 141716A) and AM 281 prominently ameliorated myocardial fibrosis, as evidenced by decreased collagen deposition and the downregulation of mRNA markers of fibrotic factors such as collagen-1, fibronectin, and TGF-β1 [27].